Pan-Cancer Interrogation of MUTYH Variants Reveals Biallelic Inactivation and Defective Base Excision Repair Across a Spectrum of Solid Tumors Clinically relevant actionable mutations were identified ...
EGFR mutation testing is crucial for NSCLC treatment, but global disparities exist in access to comprehensive molecular diagnostics. Third-generation inhibitors and combination regimens improve ...
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, ...
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...
Epidermal growth factor receptor non-small cell lung cancer (EGFR NSCLC) is a lung cancer subtype driven by EGFR gene mutations, leading to rapid tumor growth. It's prevalent particularly in Asian ...
OptiTROP-Lung04 study showed sac-TMT improved survival in pts with EGFR-mutated NSCLC who had progressed on EGFR-targeted TKIs, compared with chemotherapy.
A retrospective analysis of 1,804 patients with NSCLC undergoing next-generation sequencing (NGS) in 2019-2024 at University Hospital Würzburg (single-center cohort, including 15 patients with ...
A phase 2 clinical study (NCT03974022)found that sunvozertinib (Zegfrovy) was efficacious in 2 different doses, but ...
A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer. The targeted therapy osimertinib (Tagrisso, AstraZeneca) improved progression-free survival (PFS) by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback